UBS O'Connor’s X4 Pharmaceuticals XFOR Stock Holding History

UBS O'Connor’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,667	Closed	-$5K	–	616
2024 Q2	$5K	Buy	+6,667	New	+$218K	﹤0.01%	520

Other funds holding XFOR

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's XFOR Position: Q3 2025 in Review

UBS O'Connor sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 80,000 shares — an estimated $152K sold.

UBS O'Connor first reported a position in XFOR in Q2 2023 and held it in 9 quarters. The position peaked at $1.86M in Q1 2024. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

UBS O'Connor reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 80,000 X4 Pharmaceuticals shares in Q3 2025, an estimated $152K.
UBS O'Connor first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 9 quarters.
UBS O'Connor's X4 Pharmaceuticals position peaked at $1.86M in Q1 2024.
42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.